Catalyst Wire Dossier Catalyst Wire Dossier

T-DXd (trastuzumab deruxtecan)

trastuzumab deruxtecan · Daiichi Sankyo; AstraZeneca
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for T-DXd (trastuzumab deruxtecan), covering 2026-04-16 to 2026-04-16. Get the full timeline:

Most recent: Clinical Trial Update: Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer [Phase 3]

See pricing